Review article: Hepatorenal syndrome - How to assess response to treatment and nonpharmacological therapy

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue SUPPL. 3, 2004, Pages 49-54

  Arroyo, V ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CEFOTAXIME; CREATININE; CYTOKINE; NORADRENALIN; PLASMA SUBSTITUTE; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ADRENERGIC STIMULATION; ASCITES; BACTERIAL PERITONITIS; BRAIN DYSFUNCTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE CLASSIFICATION; HEART OUTPUT; HEART PRELOAD; HEMODIALYSIS; HEMODYNAMICS; HEMOFILTRATION; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MULTIPLE ORGAN FAILURE; OUTCOMES RESEARCH; PARACENTESIS; PERITONEUM VEIN SHUNT; PLASMA VOLUME; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE; VASOCONSTRICTION;

HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 4644273861     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02114.x     Document Type: Conference Paper

References (45)

1. Ginés A, Escorsell A, Ginés P, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993; 105: 229-36.
2. Arroyo V, Ginés P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
3. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49: 729-37.
4. Cardenas a, Uriz J, Ginés P, Arroyo V. Hepatorenal syndrome. Liver Transplant 2000; 6 (Suppl. 1): S63-71.
5. Dagher L, Patch D, Marley R, Moore K, Burroughs A. Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 2000; 14: 515-21.
6. Gentilini P, Laffi G, LaVilla G, Romanelli RG, Blendis LM. Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? J Hepatol 1999; 31: 1088-97.
7. Ginés P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol 1999; 10: 18339.
8. Bernardi M, Blendis L, Burroughs AK, Laffi G, Rodés J, Gentilini P. Hepatorenal syndrome and ascites - questions and answers. Liver 1999; 19 (Suppl.): 15-74.
9. Eckardt KU. Renal failure in liver disease. Intensive Care Med 1999; 25: 5-14.
10. Wong F, Blendis L. New challenge of hepatorenal syndrome. Prevention Treatment Hepatol 2001; 34: 1242-51.
11. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38: S69-89.
12. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal síndrome. Lancet 2003; 362: 1819-27.
13. Arroyo V, Guevara M, Ginès P. Hepatorenal síndrome in cirrosis: patogénesis and treatment. Gastroenterology 2002; 122: 1658-76.
14. Ruiz del Arbol L, Urman J, Fernandez J, et al. Systemic, renal and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-8.
15. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma Volume expansion. Hepatology 1998; 27: 35-41.
16. Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
17. Uriz J, Ginés P, Cardenas A, et al. Terlipressin plus albumin is an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.
18. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
19. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomized study. Hepatology 2002; 36: 941-8.
20. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
21. Duvoux C, Zanditenas D, Hezode C, et al. Effects of nor-adrenalin and albumin in patients with type-1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.
22. Moore KP, Wong F, Ginés P, et al. The management of ascites in cirrhosis: report of the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.
23. Gonwa TA, Morris CA, Goldstein RM, Husbert BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: Experience in 300 patients. Transplantation 1991; 91: 428-30.
24. Lerut J, Goffette P, Laterre PF, Donataccio M, Reynaert MS, Otte JB. Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPS) and liver transplantation. Hepatogastroenterology 1995; 42: 985-7.
25. Gonwa TA, Klintmalm GB, Jennings LS, Goldstein RM, Husberg B. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361-5.
26. Seu P, Wilkinson AH, Shaked A, Busuttil BW. The hepatorenal syndrome in liver transplant recipients. Am Surg 1991; 57: 806-9.
27. Rimola A, Gavaler JS, Schade RR, el-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93: 148-56.
28. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 25: 1179-85.
29. Navasa M, Feu F, Garcia-Pagan JC, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993; 17: 355-60.
30. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation and posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-6.
31. Schroeder ET, Numann PJ, Chamberlain BE. Functional renal failure in cirrhosis. Recovery after portacaval shunt. Ann Intern Med 1970; 72: 293-8.
32. Ariyan S, Sweeney T, Kerstein MD. The hepatorenal syndrome: recovery after portacaval shunt. Ann Surg 1975; 181: 847-9.
33. Brensing KA, Textro J, Perz J, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant patients with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-95.
34. Guevara M, Giné P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-22.
35. Alam I, Bass NM, LaBerge JM, Ring E, Somberg KA. Treatment of hepatorenal syndrome with the transjugular intrahepatic shunt (TIPS)(Abstract). Gastroenterology 1995; 108: A1024.
36. Ochs A, Rössle M. Haag K, et al. TIPS for hepatorenal syndrome. Hepatology 1994: 20: 114A.
37. Brensing KA, Perz J, Sauerbruch TTIPS in Hepatorenal Syndrome. In: Arroyo, V, ed. Treatment of Liver Diseases. Barcelona: Masson 1999, 53-9.
38. Linas SL, Shaffer JW, Moore EE, Good JT Jr, Giansiracusa R. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 1986; 30: 736-40.
39. Giné P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325: 829-35.
40. Giné A, Planas R, Angeli P, et al. Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis. Hepatology 1995; 22: 124-31.
41. Péez GO, Golper TA, Epstein M, Oster JR. Dialysis hemofiltration, and other extracorporeal techniques in the treatment of renal complications of liver sisease. In: Epstein, M, ed. The Kidney in Liver Disease, 4th edn. Philadelphia: Hanley & Belfus; 1996, 517-28.
42. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS, results of a prospective, randomized controlled clinical trial. Liver Transpl 2000; 6: 277-86.
43. Sorkine P, Abraham RB, Szold O, et al. Role of molecular adsorbent recycling system (MARS) in the treatment of acute exacerbation of chronic liver failure. Crit Care Med 2001; 29: 1332-6.
44. Sort P, Navasa M, Arroyo V, et al. Effect of plasma volume expansion on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.
45. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48.